Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741914 | 0.97 | CSNK1D (0.49) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL2077689 | 0.96 | LMNA (0.50) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL1407095 | 0.94 | CSNK1D (0.46) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL31715093 | 0.88 | KDM4E (0.43) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL22103841 | 0.87 | LMNA (0.42) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL22108092 | 0.87 | LMNA (0.42) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL4346096 | 0.85 | LMNA (0.54) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL1407097 | 0.84 | BAZ2B (0.41) | CSNK1DLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL2671294 | 0.84 | LMNA (0.40) | CSNK1DLMNAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21411354 | 0.81 | ALDH1A1 (0.48) | LMNAKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-1999114-B1 | PYRAZOLES AS 11-BETA-HSD-1 | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2295411-A1 | Pyrazoles as 11-beta-hsd-1 | F. Hoffmann-La Roche AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1999114-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. Hoffmann-la Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107470-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | CSNK1D 773/4885LMNA 2991/4885KDM4E 2951/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | CSNK1D 1090/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CSNK1D 1090/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CSNK1D 1090/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CSNK1D 1090/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CSNK1D 3890/4885LMNA 2715/4885KDM4E 3876/4885 |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CSNK1D 1090/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | CSNK1D 2027/4885LMNA 3454/4885KDM4E 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.